Dyne Therapeutics (DYN) Liabilities and Shareholders Equity (2019 - 2026)

Dyne Therapeutics (DYN) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $1.1 billion in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 49.77% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $3.9 billion, a 28.46% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 71.72% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.1 billion, down from $1.2 billion in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for DYN reached as high as $1.2 billion in Q4 2025 and fell as low as $165.1 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $566.9 million across 5 years, with a median of $522.3 million in 2024.
• Across the five-year window, Liabilities and Shareholders Equity sank 46.11% in 2023 and surged 318.72% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $306.3 million in 2022, then tumbled by 46.11% to $165.1 million in 2023, then jumped by 318.72% to $691.2 million in 2024, then surged by 71.72% to $1.2 billion in 2025, then fell by 9.02% to $1.1 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $1.1 billion in Q1 2026, $1.2 billion in Q4 2025, and $867.1 million in Q3 2025.